Literature DB >> 20222293

Catheter ablation of atrial fibrillation.

Richard Weachter1, Sara Baig.   

Abstract

Atrial fibrillation, the most common cardiac arrhythmia requiring treatment, has significant morbidity and mortality consequences. Pharmacologic therapy consisting of anticoagulants, AV nodal blocking agents and antiarrhythmics, remain the primary treatment. However, several nonpharmacologic therapies for the treatment of atrial fibrillation have been developed. In this review, we provide a detailed discussion of the most promising nonpharmacologic approach to the treatment of atrial fibrillation-catheter-based ablation.

Entities:  

Mesh：

Year:  2010        PMID： 20222293      PMCID： PMC6192811     

Source DB:  PubMed          Journal:  Mo Med        ISSN： 0026-6620


  10 in total

1.  A comparison of rate control and rhythm control in patients with atrial fibrillation.

Authors:  D G Wyse; A L Waldo; J P DiMarco; M J Domanski; Y Rosenberg; E B Schron; J C Kellen; H L Greene; M C Mickel; J E Dalquist; S D Corley
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

Review 2.  Atrial fibrillation ablation: state of the art.

Authors:  Carlo Pappone; Vincenzo Santinelli
Journal:  Am J Cardiol       Date:  2005-10-05       Impact factor: 2.778

Review 3.  Catheter ablation therapy for atrial fibrillation.

Authors:  Joseph E Marine; Jun Dong; Hugh Calkins
Journal:  Prog Cardiovasc Dis       Date:  2005 Nov-Dec       Impact factor: 8.194

Review 4.  Should atrial fibrillation ablation be considered first-line therapy for some patients? Why atrial fibrillation ablation should be considered first-line therapy for some patients.

Authors:  Atul Verma; Andrea Natale
Journal:  Circulation       Date:  2005-08-23       Impact factor: 29.690

Review 5.  HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation.

Authors:  Hugh Calkins; Josep Brugada; Douglas L Packer; Riccardo Cappato; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; David E Haines; Michel Haissaguerre; Yoshito Iesaka; Warren Jackman; Pierre Jais; Hans Kottkamp; Karl Heinz Kuck; Bruce D Lindsay; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Andrea Natale; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Jeremy N Ruskin; Richard J Shemin
Journal:  Heart Rhythm       Date:  2007-04-30       Impact factor: 6.343

Review 6.  The stepwise ablation approach for chronic atrial fibrillation--evidence for a cumulative effect.

Authors:  Mark D O'Neill; Pierre Jaïs; Yoshihide Takahashi; Anders Jönsson; Frédéric Sacher; Mélèze Hocini; Prashanthan Sanders; Thomas Rostock; Martin Rotter; Andrej Pernat; Jacques Clémenty; Michel Haïssaguerre
Journal:  J Interv Card Electrophysiol       Date:  2006-11-14       Impact factor: 1.900

7.  Late recurrent arrhythmias after ablation of atrial fibrillation: incidence, mechanisms, and treatment.

Authors:  Richard Kobza; Gerhard Hindricks; Hildegard Tanner; Petra Schirdewahn; Anja Dorszewski; Christopher Piorkowski; Jin-Hong Gerds-Li; Hans Kottkamp
Journal:  Heart Rhythm       Date:  2004-12       Impact factor: 6.343

8.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.

Authors:  A S Go; E M Hylek; K A Phillips; Y Chang; L E Henault; J V Selby; D E Singer
Journal:  JAMA       Date:  2001-05-09       Impact factor: 56.272

Review 9.  Atrial-fibrillation ablation should be considered first-line therapy for some patients.

Authors:  Atul Verma
Journal:  Curr Opin Cardiol       Date:  2008-01       Impact factor: 2.161

Review 10.  Atrial fibrillation: unanswered questions and future directions.

Authors:  Vivek Y Reddy
Journal:  Cardiol Clin       Date:  2009-02       Impact factor: 2.213
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.